This is a pilot study presenting first clinical experience of [89Zr]Zr-PSMA-617 PET/CT including biodistribution, radiation dosimetry estimates, and analysis of tumor lesion imaging in patients with BCR of prostate cancer. This evidence concerns the gene BCR and prostate carcinoma.